Digital Pathology In COVID-19

Context:

Digital pathology technologies are now being included into ordinary workflow in pathology practises. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes the coronavirus disease 2019 (COVID-19), which emerged as a pandemic throughout 2020, had a substantial impact on the world’s population in a number of areas, including pathology.

Years ago, digital pathology was created to enable pathologists to remotely work together on cases and increase the precision of diagnostic procedures by exchanging digital pictures among laboratories. The COVID-19 epidemic has pushed the widespread adoption of digital pathology for pathology diagnosis rendered remotely

Effects Of COVID-19 In Pathology

The 2020 COVID-19 problem has had, and will continue to have, a wide range of effects on pathology and healthcare. Lack of staff due to an increase in infections may force pathology staff to fill more urgent responsibilities in other hospital departments.

Impact Of COVID-19 In Digital Pathology

The COVID-19 outbreak has had a substantial impact on pathology services. Digital pathology can be helpful to “safeguard clinical services and pathology-based research in the current environment and in the future.” This digital-based approach to diagnosis provides a novel viewpoint on the assessment of surgical pathology slides from formalin-fixed, paraffin-embedded tissue (FFPE). The pathologist is no longer limited to working in their office beneath an optical microscope. The “social interaction” of pathologists, which includes their interactions with physicians and even patients, may also be impacted.

COVID-19 Companies

CanSino Biological

Moderna,

University of Oxford

BioNTech

Novavax

Inovio Pharmaceuticals

Beijing Institute of Biological Products/Sinophar

Chinese Academy of Medical Sciences.

Recommended Articles

Leave a Reply

Your email address will not be published. Required fields are marked *